eGFR Interpretation by Decade of Life

What eGFR Actually Measures

EGFR estimates the volume of blood the kidneys filter per minute, normalized to a body surface area of 1.73 m². The 2021 CKD-EPI equation replaced older race-based formulas after evidence showed those formulas systematically overestimated kidney function in Black patients, delaying CKD diagnosis. The National Kidney Foundation and American Society of Nephrology recommended this transition in 2021.

The CKD-EPI 2021 Equation

CKD-EPI 2021 uses serum creatinine, age, and sex. It does not include race. Validation studies in a pooled cohort of over 10,000 participants showed the race-free equation had a bias of only 3.7 mL/min/1.73 m² compared to measured GFR, which is within clinically acceptable margins. Details of that validation appear in the New England Journal of Medicine.

Why eGFR Matters for Hormone and Metabolic Therapy

Kidneys clear or activate nearly every drug used in hormone and metabolic medicine. Metformin accumulates when eGFR falls below 45, raising lactic acidosis risk. Semaglutide (Ozempic, Wegovy) does not require dose adjustment down to eGFR 15, but the kidneys handle much of the fluid and electrolyte burden during rapid weight loss. Testosterone and its metabolites depend on renal clearance for elimination of conjugated estrogens. Knowing the patient's eGFR before prescribing is not a formality. It changes the prescription.

KDIGO CKD Staging: The Framework Every Clinician Uses

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 update retains five eGFR-based stages, each carrying distinct risk profiles and management implications. The full KDIGO 2024 CKD Clinical Practice Update is available via the official KDIGO site.

The Five eGFR Stages

• G1: eGFR 90 or higher. Normal or high filtration. CKD diagnosis requires a concurrent marker of kidney damage (albuminuria, structural abnormality, etc.).
• G2: eGFR 60 to 89. Mildly decreased. Often physiologic in older adults. Requires albuminuria or other damage marker to diagnose CKD.
• G3a: eGFR 45 to 59. Mild-to-moderately decreased. Metformin dose reduction begins here.
• G3b: eGFR 30 to 44. Moderately-to-severely decreased. Metformin should be stopped. Nephrology referral appropriate.
• G4: eGFR 15 to 29. Severely decreased. Preparation for renal replacement therapy begins.
• G5: eGFR below 15. Kidney failure.

Albuminuria Modifies the Stage

An eGFR alone does not fully define CKD risk. KDIGO pairs eGFR stage with albumin-to-creatinine ratio (ACR) in three categories: A1 (<30 mg/g), A2 (30 to 300 mg/g), A3 (>300 mg/g). A patient with eGFR 65 and ACR 250 mg/g carries a higher cardiovascular and progression risk than eGFR 65 with ACR 10 mg/g. This combined risk matrix is detailed in the KDIGO 2024 update.

eGFR in Your 20s and 30s: What "Normal" Looks Like

Healthy adults in their 20s typically show eGFR values between 100 and 130 mL/min/1.73 m². The Rochester Epidemiology Project measured mean measured GFR of 107 mL/min/1.73 m² in adults aged 20 to 29. Cross-sectional data from that cohort are cited in a landmark aging-and-GFR paper in JASN.

Red Flags at This Age

An eGFR below 90 in a person under 35 is abnormal until proven otherwise. Common causes include IgA nephropathy (peak onset age 20 to 30), lupus nephritis, hypertensive nephrosclerosis from uncontrolled early-onset hypertension, or a single functioning kidney. These are not age-related changes.

Optimal Target in the 20s, 30s

From a longevity-medicine standpoint, an eGFR of 100 or higher at this age indicates adequate functional reserve. Values between 90 and 100 are acceptable but warrant a baseline urinalysis and ACR to exclude subclinical damage. Any value under 60 in this age group triggers same-day nephrology consultation.

eGFR in Your 40s: The Inflection Point

Glomerular filtration rate peaks in early adulthood and begins a measurable decline around age 40. The rate accelerates with hypertension, metabolic syndrome, and insulin resistance, all of which are common in the patient population seeking GLP-1 and TRT therapy. A cross-sectional analysis in the Baltimore Longitudinal Study of Aging documented a mean GFR decline of 0.75 to 1.0 mL/min/1.73 m² per year starting in the fourth decade. Those longitudinal data appear in JASN.

Expected Range at 40 to 49

A 45-year-old with an eGFR of 92 is doing well. An eGFR of 72 at the same age may be physiologic but deserves scrutiny. Apply the simple benchmark: subtract 1 point per year from a baseline of ~120 at age 20. A 45-year-old would be expected around 95 to 105 by that formula, so 72 represents a 20 to 30 point deficit that warrants a urine ACR.

Metformin and GLP-1 Decisions at This Age

At eGFR 45 to 59, the FDA label for metformin advises dose reduction and monitoring every 3 to 6 months. The FDA prescribing information for metformin states it is contraindicated when eGFR falls below 30. Semaglutide (Ozempic) and tirzepatide (Mounjaro) do not require dose adjustment at any eGFR above 15 per their respective FDA labels, making them safer choices than metformin in mild CKD.

eGFR in Your 50s: Where Clinical Decisions Multiply

The 50s are the decade when eGFR values most often cross the thresholds that change prescribing. The mean eGFR in a population-based U.S. Cohort aged 50 to 59 was approximately 83 mL/min/1.73 m² in the Third National Health and Nutrition Examination Survey (NHANES III), but individuals with hypertension or diabetes showed means closer to 71. NHANES-derived eGFR distributions are published by the CDC.

What Is "Normal" at 50 to 59?

Using the age-decay benchmark:

• Age 50: expected eGFR approximately 90 to 100
• Age 55: expected eGFR approximately 85 to 95
• Age 59: expected eGFR approximately 80 to 90

An eGFR below 60 at any point in this decade places the individual in CKD G3a and changes management meaningfully.

TRT and eGFR in the 50s

Testosterone therapy increases erythropoiesis and can raise creatinine slightly through increased muscle mass, which may lower the calculated eGFR by 3 to 5 points without any actual decline in filtration. Clinicians should obtain a cystatin C-based eGFR (eGFRcys) when creatinine-based eGFR drops unexpectedly after TRT initiation, since cystatin C is not affected by muscle mass. A comparison of creatinine- vs. Cystatin C-based eGFR equations appears in JASN.

Screening Intensity

KDIGO recommends monitoring eGFR and ACR at least annually when eGFR is 45 to 59 and at least twice yearly at 30 to 44. That monitoring schedule is part of the KDIGO 2024 update.

eGFR in Your 60s: Separating Aging from Disease

A 65-year-old with an eGFR of 65 mL/min/1.73 m² and normal ACR may simply reflect the expected loss of nephron mass with age. Or it may be early diabetic nephropathy. Context is everything. The Chronic Renal Insufficiency Cohort (CRIC) study, which enrolled 3,939 adults with CKD, found that annual eGFR decline rates ranged from 0.9 to 4.3 mL/min/1.73 m² per year depending on the presence of diabetes and proteinuria. CRIC study methods and outcomes are published in JASN.

Age-Adjusted vs. Absolute Thresholds

Some nephrologists argue that an eGFR of 60 to 70 in a healthy 68-year-old should not automatically carry a CKD label, because it may represent physiologic aging rather than pathologic nephron loss. The KDIGO 2024 update acknowledges this tension and recommends that an eGFR of 60 to 89 in the absence of other kidney damage markers not be labeled CKD in older adults without further evidence of progression. See KDIGO 2024.

GLP-1 Therapy in the 60s

The FLOW trial, published in 2024 in the New England Journal of Medicine, randomized 3,533 patients with type 2 diabetes and CKD to semaglutide 1.0 mg weekly or placebo. Semaglutide reduced the composite kidney outcome (sustained eGFR decline of 50%, kidney failure, or renal death) by 24% compared to placebo (HR 0.76, 95% CI 0.66 to 0.88, P<0.001). The FLOW trial is published in the NEJM. This makes semaglutide the first GLP-1 receptor agonist with a dedicated kidney outcomes trial showing benefit, and it is particularly relevant in the 60s when eGFR decline accelerates.

eGFR in Your 70s: Managing the Threshold Zone

Most adults in their 70s have eGFR values between 55 and 80 mL/min/1.73 m². An eGFR of 58 in a 74-year-old with no albuminuria and stable values over 3 years is vastly different from a 74-year-old whose eGFR dropped from 80 to 58 in 18 months. Rate of change matters as much as absolute value.

The Stability Test

KDIGO defines a clinically significant eGFR decline as a drop of 5 mL/min/1.73 m² or more within 12 months, or 10 mL/min/1.73 m² within 5 years, confirmed on at least two measurements. This definition is from the KDIGO 2024 update. A single low result is not enough to diagnose progression.

Drug Safety at eGFR 30 to 59 in Older Adults

At eGFR 30 to 44, the following changes apply for common HealthRX therapies:

• Metformin: stop at eGFR <30; reduce dose and monitor at 30 to 45
• Semaglutide (Ozempic/Wegovy): no dose adjustment needed above eGFR 15, per FDA label
• Tirzepatide (Mounjaro/Zepbound): no dose adjustment needed above eGFR 15, per FDA label
• Testosterone cypionate: no mandatory dose reduction, but watch for fluid retention and erythrocytosis increasing cardiovascular risk in the setting of reduced renal clearance
• SGLT2 inhibitors (empagliflozin, dapagliflozin): efficacy is reduced below eGFR 45 for glycemic control but cardiorenal benefit persists to eGFR 20 per 2023 ADA Standards of Care ADA Standards of Care in Diabetes 2023

NSAID Avoidance

Ibuprofen, naproxen, and other NSAIDs reduce renal blood flow acutely and can drop eGFR by 10 to 15 points in older adults already in the G3 range. Patients on TRT who use NSAIDs for musculoskeletal pain need explicit counseling to switch to acetaminophen.

eGFR in Your 80s and Beyond: Recalibrating Expectations

Population data from NHANES show that median eGFR in adults aged 80 and older is approximately 60 to 65 mL/min/1.73 m². NHANES data on eGFR by age are available from the CDC. This means that by conventional thresholds, a substantial fraction of octogenarians technically qualify for CKD G2 or G3a based on eGFR alone.

When to Label, When Not To

The KDIGO position is nuanced: applying a CKD label to an 85-year-old with eGFR 62 and no albuminuria, no structural abnormality, and stable values over several years may cause unnecessary anxiety and over-medicalization. A better clinical question is whether the eGFR is stable, what the ACR shows, and whether cardiovascular risk management is optimized.

Longevity Medicine Perspective

In longevity-medicine practice, the goal is not merely to avoid CKD staging but to preserve as much functional renal reserve as possible across decades. A patient who enters their 80s with an eGFR of 75 has substantially more physiologic buffer than one who enters with 50, even if both are technically "normal for age." The HealthRX eGFR Decade Framework categorizes patients into three tiers based on age-adjusted expected eGFR and observed value:

• Tier 1 (Optimal): Observed eGFR within 10 points above the age-expected mean. No action beyond annual monitoring.
• Tier 2 (Watch): Observed eGFR 10 to 25 points below age-expected mean. Annual ACR, blood pressure optimization, dietary protein review, and 6-month recheck.
• Tier 3 (Act): Observed eGFR 25 or more points below age-expected mean, or any year-over-year decline exceeding 5 mL/min/1.73 m². Nephrology referral and medication safety review within 90 days.

eGFR and Drug Dosing: A Practical Reference Table

The table below summarizes eGFR-based prescribing checkpoints for the drugs most commonly used in HealthRX clinical programs.

| Drug | No restriction | Caution / reduce | Contraindicated | |---|---|---|---| | Metformin | eGFR 45 or higher | eGFR 30 to 44 | eGFR <30 | | Semaglutide (sc) | eGFR 15 or higher | N/A | eGFR <15 (limited data) | | Tirzepatide (sc) | eGFR 15 or higher | N/A | eGFR <15 (limited data) | | Testosterone cypionate (im) | Any eGFR | eGFR <30 (monitor erythrocytosis) | No hard cutoff | | Empagliflozin | eGFR 20 or higher | eGFR 20 to 44 (glycemic benefit reduced) | eGFR <20 | | Dapagliflozin (HF/CKD) | eGFR 25 or higher | Monitor at 25 to 44 | eGFR <25 |

Sources: FDA metformin label, ADA Standards of Care 2023, KDIGO 2024

How to Interpret a Single eGFR Result

A single eGFR value has limited diagnostic weight. Creatinine fluctuates with hydration, protein intake, exercise, and muscle catabolism. The American Society of Nephrology recommends confirming any eGFR below 60 with a repeat test at least 3 months later before assigning a CKD stage. This recommendation appears in the 2024 KDIGO update.

Acute vs. Chronic Reduction

A drop in eGFR over days suggests acute kidney injury (AKI), which has different causes and management than CKD. Dehydration, contrast agents, NSAIDs, and sepsis are common AKI triggers. Chronic eGFR reduction develops over months to years. The clinical distinction requires serial measurements and clinical context.

Cystatin C as a Confirmatory Test

When creatinine-based eGFR is borderline or suspected to be misleading (e.g., very high or very low muscle mass, TRT-related muscle gain), cystatin C provides an independent estimate. The CKD-EPI cystatin C equation shows lower bias than creatinine-based equations in older adults and in individuals with sarcopenia or extreme muscularity. A head-to-head comparison is available in JASN. Cystatin C testing is covered by Medicare for patients with CKD.

Protecting and Preserving eGFR Over Time

EGFR decline is not inevitable at the rate most people experience. The 12-year SPRINT trial sub-analysis showed that intensive blood pressure control (target systolic <120 mmHg) slowed eGFR decline and reduced CKD progression compared to standard control (target <140 mmHg), with a hazard ratio of 0.81 (P<0.001) for the composite kidney outcome. SPRINT renal outcomes are published in NEJM.

Blood Pressure

The 2021 ACC/AHA guidelines target systolic blood pressure below 130 mmHg in adults with CKD, and below 120 mmHg if proteinuria is present. ACE inhibitors and ARBs are first-line agents because they reduce intraglomerular pressure and proteinuria. The ACC/AHA hypertension guideline is available via JACC.

Diet

Protein intake above 1.3 g/kg/day may accelerate eGFR decline in patients with CKD G3 or worse. A meta-analysis of 17 randomized trials found that low-protein diets (0.6 to 0.8 g/kg/day) reduced the risk of kidney failure by 32% compared to unrestricted protein in CKD patients (RR 0.68, 95% CI 0.55 to 0.84). That meta-analysis is indexed at PubMed. Patients on TRT or GLP-1 therapy who are simultaneously doing high-protein dietary protocols should be counseled on this trade-off.

Weight Loss

The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% placebo. Published in NEJM. Obesity-driven hyperfiltration (eGFR paradoxically elevated above 120 due to glomerular hypertension) normalizes with weight loss, so a post-weight-loss drop in eGFR from 125 to 100 may actually represent improved kidney health rather than harm.

Glycemic Control

In the UKPDS 33 trial, intensive glucose control (target HbA1c 7.0%) reduced microvascular complications, including nephropathy, by 25% compared to conventional control over 10 years. UKPDS 33 is available in The Lancet. Every 1% reduction in HbA1c correlates with a measurable slowing of eGFR decline in type 2 diabetes.

Clinical Takeaways by Age Group

| Age decade | Expected eGFR range | Optimal eGFR target | Key action threshold | |---|---|---|---| | 20s | 100 to 130 | 110 or higher | <90 triggers workup | | 30s | 95 to 120 | 100 or higher | <90 triggers workup | | 40s | 85 to 110 | 95 or higher | <75 triggers ACR | | 50s | 75 to 100 | 90 or higher | <60 triggers staging | | 60s | 65 to 90 | 80 or higher | <60 or rapid decline triggers nephrology | | 70s | 55 to 80 | 70 or higher | <45 triggers med review | | 80s+ | 50 to 75 | Stable >60 | Annual ACR; decline >5/yr triggers referral |

The KDIGO guideline states: "GFR below 60 mL/min/1.73 m² is a diagnostic criterion for CKD regardless of other markers of kidney disease because it implies loss of half or more of the normal adult kidney function." KDIGO 2024.

The ADA 2023 Standards of Care state: "In patients with type 2 diabetes and CKD, use of an SGLT2 inhibitor with proven kidney benefit is recommended to reduce the risk of CKD progression and cardiovascular events." ADA 2023.

Order a repeat eGFR with cystatin C confirmation and a urine ACR if your current creatinine-based eGFR falls more than 15 mL/min/1.73 m² below the age-expected mean shown in the table above.